Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

Background: Adalimumab induced clinical remission after four weeks in patients with active Crohn’s disease in the CLASSIC I trial. Objective: To evaluate long term efficacy and safety of adalimumab ...

The symptoms of Crohn’s disease vary from person to person. They may come and go, and sometimes certain foods can trigger worsened symptoms, such as abdominal pain and diarrhea. Although no one ...

Patients with severe bowel disease are set to benefit from a new drug that can eliminate their distressing symptoms in only three months. The once-a-month jab, guselkumab, treats Crohn’s and ...

A switch to ustekinumab was considered as an alternative.3 However, financial constraints and the patient’s concern about a Crohn’s flare with discontinuation of infliximab led to the continuation of ...

ncl.ac.uk The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and ...

Subcutaneous guselkumab showed significant clinical remission and endoscopic response in moderate to severe Crohn's disease, with no added safety concerns. The GRAVITI study supported guselkumab's ...

A newly approved blood test could make it easier and less costly to detect Alzheimer's disease, allowing clinicians to diagnose and treat the condition at an earlier stage. The most common tests for ...

Joyce Siette receives funding from the National Health and Medical Research Council on a Targeted Call for Research on cultural, ethnic and linguistic diversity in dementia research. A new study ...

Kennedy Jr., the health secretary, set forth their vision on Thursday for how to “make America healthy again” with the release of an expansive report on a crisis of chronic disease in children.